Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Experts are predicting strong results driven by the robust sales of Lilly's blockbuster treatments, particularly its insulin portfolio. However, there are also concerns about potential challenges from